<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2023-13-3-11-19</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-1164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group></article-categories><title-group><article-title>Прогностическая роль белков PD-L1 И P53 при плоскоклеточной карциноме ротоглотки в зависимости от статуса вируса папилломы человека</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic role of PD-L1 and P53 proteins in oropharyngeal squamous cell carcinoma depending on the status of the human papilloma virus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полатова</surname><given-names>Д. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Polatova</surname><given-names>D.  Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Джамила Ш. Полатова, д. м. н., заведующая кафедрой онкологии и медицинской радиологии;  научный руководитель отделения опухолей опорно-двигательной системы</p><p>Ташкент</p></bio><bio xml:lang="en"><p>Djamila Sh. Polatova, MD, PhD, DSc, Head of the Department of Oncology and Medical Radiology; Scientific Director of the Department of Tumors of the Musculoskeletal System</p><p>Tashkent</p><p> </p></bio><email xlink:type="simple">polatova.dj@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гильдиева</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Gildieva</surname><given-names>М.  S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маргарита С. Гильдиева, д. биол. н., руководитель лаборатории генетики опухолей</p><p>Ташкент</p></bio><bio xml:lang="en"><p>Margarita S. Gildieva, DSc biol., Head of the Laboratory of Tumors Genetics</p><p>Tashkent</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мадаминов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Madaminov</surname><given-names>A.  Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахмад Ю. Мадаминов, научный соискатель кафедры онкологии и медицинской радиологии </p><p>Ташкент</p></bio><bio xml:lang="en"><p>Akhmad Yu. Madaminov, scientific aspirant</p><p>Tashkent </p></bio><email xlink:type="simple">akhmad.madaminov@inbox.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савкин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Savkin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр В. Савкин, базовый докторант</p><p>Ташкент</p></bio><bio xml:lang="en"><p>Aleksandr V. Savkin, basic doctoral student</p><p>Tashkent</p><p> </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скляров</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sklyarov</surname><given-names>D.  S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Денис С. Скляров</p><p>Ташкент</p></bio><bio xml:lang="en"><p>Denis S. Sklyarov</p><p>Tashkent</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ташкентский государственный стоматологический институт; Республиканский специализированный научно-практический медицинский центр онкологии и радиологии</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Tashkent State Dental Institute; Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology</institution><country>Uzbekistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Республиканский специализированный научно-практический медицинский центр онкологии и радиологии</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology</institution><country>Uzbekistan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Ташкентский государственный стоматологический институт</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Tashkent State Dental Institute</institution><country>Uzbekistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>08</day><month>11</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><fpage>11</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полатова Д.Ш., Гильдиева М.С., Мадаминов А.Ю., Савкин А.В., Скляров Д.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Полатова Д.Ш., Гильдиева М.С., Мадаминов А.Ю., Савкин А.В., Скляров Д.С.</copyright-holder><copyright-holder xml:lang="en">Polatova D.S., Gildieva М.S., Madaminov A.Y., Savkin A.V., Sklyarov D.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/1164">https://www.malignanttumors.org/jour/article/view/1164</self-uri><abstract><sec><title>Введение</title><p>Введение: Рост случаев ВПЧ-ассоциированной плоскоклеточной карциномы ротоглотки (ПККР), а также появление у 20–25% пациентов с ВПЧ + ПККР рецидивов в течение 3 лет вызвало интерес к исследованию ВПЧ статуса таких больных. Это стало мощным стимулом широкого использования биомаркеров. В связи с этим для выявления пациентов с высоким риском рецидива и смерти необходимо использование различных прогностических маркеров.</p></sec><sec><title>Методы</title><p>Методы: В исследование были включены 62 пациента с ПККР T1–4N0–3M0 (7-е издание, AJCC), пролеченных в 2015–2020 годах в Республиканском специализированном научно-практическом медицинском центре онкологии и радиологии и в Ташкентском и Самаркандском городских филиалах. Было изучено прогностическое значение белков PD-L1 и p53 при ПККР с учетом ВПЧ статуса. Кроме того, была проанализирована взаимосвязь между PD-L1, р53 и статусом ВПЧ, а также влияние их на выживаемость пациентов с ПККР.</p></sec><sec><title>Результаты</title><p>Результаты: Положительный ВПЧ статус вместе с высокой экспрессией PD-L1 незначительно улучшают показатели общей выживаемости пациентов по сравнению с отсутствием ВПЧ (p = 0,261). Мутантный тип белка р53 имеет отрицательную корреляцию с ВПЧ статусом и снижает время дожития (p &lt; 0,001). Дикий тип р53 встречается у небольшого числа больных, он демонстрирует положительную корреляцию со статусом ВПЧ и является предиктором, снижающим риск смерти (p = 0,01).</p></sec><sec><title>Заключение</title><p>Заключение: Положительный ВПЧ статус не всегда является надежным предиктором при стратификации риска развития опухоли для больных ПККР, поскольку для повышения ценности прогностических предикторов кроме ВПЧ статуса необходимо идентифицировать дополнительные факторы, взаимосвязанные с развитием ПККР.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background: At a time lots of cases of HPV associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) are on the rise and excellent outcomes are seen when comparing HPV-OPSCC, identification of HPV status has become a powerful and widely used marker. Despite this, 20–25 % of HPV + OPSCC patients relapse within 3 years. The most significant barrier to identifying patients at high risk of relapse and death is the lack of clinically useful prognostic markers.</p></sec><sec><title>Methods</title><p>Methods: The study included 62 patients treated with OPSCC T1–4N0–3M0 (7th edition, AJCC) in 2015–2020 in clinics located in two large cities of Uzbekistan (Tashkent and Samarkand). The study analyzed the prognostic value of PD-L1 and p53 proteins in OPSCC, taking into account HPV status. In addition, the relationship between PD-L1, p53 and HPV status was analyzed, as well as their impact on patient survival.</p></sec><sec><title>Results</title><p>Results: Positive HPV status with positive PD-L1 expression improves overall survival of patients compared to their negativity (p = 0.261). The mutant type of p53 protein has a negative correlation with HPV status, which reduces survival time (p &lt; 0.001). Wild type p53 is detected in a small number of patients, but it shows a positive correlation with HPV status as a strong protective factor that reduces the risk of death (p = 0.01).</p></sec><sec><title>Conclusion</title><p>Conclusion: Positive HPV status is not always a reliable predictor of risk stratification for patients with OPSCC, because additional indicators associated with the development of OPSCC need to be identified to reinforce the value of predictive predictors other than HPV status.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>плоскоклеточная карцинома ротоглотки</kwd><kwd>вирус папилломы человека</kwd><kwd>экспрессия белка</kwd><kwd>р16INK4a</kwd><kwd>PD-L1</kwd><kwd>р53</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oropharyngeal squamous cell carcinoma</kwd><kwd>human papillomavirus</kwd><kwd>protein expression</kwd><kwd>p16INK4a</kwd><kwd>PD-L1</kwd><kwd>p53</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018 : a worldwide incidence analysis. Lancet Glob Health. 2020 ; 8 (2) : e180-e190. doi: 10.1016/S2214-109X(19)30488-7.</mixed-citation><mixed-citation xml:lang="en">de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018 : a worldwide incidence analysis. Lancet Glob Health. 2020 ; 8 (2) : e180-e190. doi: 10.1016/S2214-109X(19)30488-7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 ; 29 (32) : 4294–4301. doi: 10.1200/JCO.2011.36.4596.</mixed-citation><mixed-citation xml:lang="en">Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 ; 29 (32) : 4294–4301. doi: 10.1200/JCO.2011.36.4596.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 ; 33 (29) : 3235–3242. doi: 10.1200/JCO.2015.61.6995.</mixed-citation><mixed-citation xml:lang="en">Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 ; 33 (29) : 3235–3242. doi: 10.1200/JCO.2015.61.6995.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Carlander AF, Jakobsen KK, Bendtsen SK, et al. A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide. Viruses. 2021 ; 13 (7) : 1326. doi: 10.3390/v13071326.</mixed-citation><mixed-citation xml:lang="en">Carlander AF, Jakobsen KK, Bendtsen SK, et al. A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide. Viruses. 2021 ; 13 (7) : 1326. doi: 10.3390/v13071326.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Global Cancer Observatory, https://gco.iarc.fr/.</mixed-citation><mixed-citation xml:lang="en">Global Cancer Observatory, https://gco.iarc.fr/.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap : differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015 ; 136 (12) : 2752–2760. doi: 10.1002/ijc.29082.</mixed-citation><mixed-citation xml:lang="en">Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap : differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015 ; 136 (12) : 2752–2760. doi: 10.1002/ijc.29082.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sinha P, Karadaghy OA, Doering MM, Tuuli MG, Jackson RS, Haughey BH. Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach : A systematic review and meta-analysis. Oral Oncol. 2018 ; 86 : 121–131. doi: 10.1016/j.oraloncology.2018.09.018.</mixed-citation><mixed-citation xml:lang="en">Sinha P, Karadaghy OA, Doering MM, Tuuli MG, Jackson RS, Haughey BH. Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach : A systematic review and meta-analysis. Oral Oncol. 2018 ; 86 : 121–131. doi: 10.1016/j.oraloncology.2018.09.018.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мудунов А. М. Вирус папилломы человека – новый этиологический фактор в развитии рака органов головы и шеи. Проблемы и перспективы их решения. Эпидемиология и Вакцинопрофилактика. 2018 ; 17 (5) : 100–105. doi: 10.31631/2073-3046-2018-17-5-100-105.</mixed-citation><mixed-citation xml:lang="en">Мудунов А. М. Вирус папилломы человека – новый этиологический фактор в развитии рака органов головы и шеи. Проблемы и перспективы их решения. Эпидемиология и Вакцинопрофилактика. 2018 ; 17 (5) : 100–105. doi: 10.31631/2073-3046-2018-17-5-100-105.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Белякова Е. Н. Клинико-эпидемиологическая характеристика и факторы риска ВПЧ-ассоциированного рака головы и шеи в России : результаты выборочного исследования. Анализ риска здоровья. 2022 ; 1 : 72–80. doi: 10.21668/health.risk/2022.1.07.</mixed-citation><mixed-citation xml:lang="en">Белякова Е. Н. Клинико-эпидемиологическая характеристика и факторы риска ВПЧ-ассоциированного рака головы и шеи в России : результаты выборочного исследования. Анализ риска здоровья. 2022 ; 1 : 72–80. doi: 10.21668/health.risk/2022.1.07.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer : epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022 ; 19 (5) : 306–327. doi: 10.1038/s41571-022-00603-7.</mixed-citation><mixed-citation xml:lang="en">Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer : epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022 ; 19 (5) : 306–327. doi: 10.1038/s41571-022-00603-7.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis JS Jr, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas : Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018 ; 142 (5) : 559–597. doi: 10.5858/arpa.2017-0286-CP.</mixed-citation><mixed-citation xml:lang="en">Lewis JS Jr, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas : Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018 ; 142 (5) : 559–597. doi: 10.5858/arpa.2017-0286-CP.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Han Y, Liu D, Li L. PD-1 / PD-L1 pathway : current researches in cancer. Am J Cancer Res. 2020 ; 10 (3) : 727–742. Published 2020 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Han Y, Liu D, Li L. PD-1 / PD-L1 pathway : current researches in cancer. Am J Cancer Res. 2020 ; 10 (3) : 727–742. Published 2020 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Golrokh Mofrad M, Taghizadeh Maleki D, Faghihloo E. The roles of programmed death ligand 1 in virus-associated cancers. Infect Genet Evol. 2020 ; 84 : 104368. doi: 10.1016/j.meegid.2020.104368.</mixed-citation><mixed-citation xml:lang="en">Golrokh Mofrad M, Taghizadeh Maleki D, Faghihloo E. The roles of programmed death ligand 1 in virus-associated cancers. Infect Genet Evol. 2020 ; 84 : 104368. doi: 10.1016/j.meegid.2020.104368.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer : molecular mechanisms and polymorphisms. Immunogenetics. 2018 ; 70 (2) : 73–86. doi: 10.1007/s00251-017-1015-5.</mixed-citation><mixed-citation xml:lang="en">Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer : molecular mechanisms and polymorphisms. Immunogenetics. 2018 ; 70 (2) : 73–86. doi: 10.1007/s00251-017-1015-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. J Cell Biochem. 2016 ; 117 (12) : 2682–2692. doi: 10.1002/jcb.25592.</mixed-citation><mixed-citation xml:lang="en">Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. J Cell Biochem. 2016 ; 117 (12) : 2682–2692. doi: 10.1002/jcb.25592.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Chen C, Xu Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016 ; 531 (7595) : 471–475. doi: 10.1038/nature17157.</mixed-citation><mixed-citation xml:lang="en">Liu Y, Chen C, Xu Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016 ; 531 (7595) : 471–475. doi: 10.1038/nature17157.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Caponio VCA, Troiano G, Adipietro I, et al. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. Br J Cancer. 2020 ; 123 (8) : 1302–1314. doi: 10.1038/s41416-020-0984-6.</mixed-citation><mixed-citation xml:lang="en">Caponio VCA, Troiano G, Adipietro I, et al. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. Br J Cancer. 2020 ; 123 (8) : 1302–1314. doi: 10.1038/s41416-020-0984-6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018 ; 37 (1) : 30. Published 2018 Feb 15. doi: 10.1186/s13046-018-0705-7.</mixed-citation><mixed-citation xml:lang="en">Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018 ; 37 (1) : 30. Published 2018 Feb 15. doi: 10.1186/s13046-018-0705-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Стукань А. И., Чухрай О. Ю., Порханов В. А. и др. Орофарингеальная карцинома, ассоциированная с вирусом папилломы человека : тенденции эпидемиологии и методы выявления вируса в опухоли. Опухоли головы и шеи. 2018 ; 8 (3) : 77–83.</mixed-citation><mixed-citation xml:lang="en">Стукань А. И., Чухрай О. Ю., Порханов В. А. и др. Орофарингеальная карцинома, ассоциированная с вирусом папилломы человека : тенденции эпидемиологии и методы выявления вируса в опухоли. Опухоли головы и шеи. 2018 ; 8 (3) : 77–83.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
